MX2015007712A - Polipeptidos del factor vii de accion corta. - Google Patents

Polipeptidos del factor vii de accion corta.

Info

Publication number
MX2015007712A
MX2015007712A MX2015007712A MX2015007712A MX2015007712A MX 2015007712 A MX2015007712 A MX 2015007712A MX 2015007712 A MX2015007712 A MX 2015007712A MX 2015007712 A MX2015007712 A MX 2015007712A MX 2015007712 A MX2015007712 A MX 2015007712A
Authority
MX
Mexico
Prior art keywords
variants
factor vii
short
acting factor
vii polypeptides
Prior art date
Application number
MX2015007712A
Other languages
English (en)
Inventor
Maxine Bauzon
Terry Hermiston
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51022016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015007712(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of MX2015007712A publication Critical patent/MX2015007712A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Abstract

Se divulgan péptidos del Factor VII de acción corta. Una vida media acortada es deseable para el tratamiento de hemorragia aguda y trastornos similares. La modificación de la sialización y/o de la glucosilación del Factor VII y de variantes del mismo produjo péptidos útiles en el tratamiento de afecciones de hemorragia aguda.
MX2015007712A 2012-12-24 2013-12-23 Polipeptidos del factor vii de accion corta. MX2015007712A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745674P 2012-12-24 2012-12-24
US201361787026P 2013-03-15 2013-03-15
PCT/US2013/077405 WO2014105784A1 (en) 2012-12-24 2013-12-23 Short-acting factor vii polypeptides

Publications (1)

Publication Number Publication Date
MX2015007712A true MX2015007712A (es) 2015-09-07

Family

ID=51022016

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015007712A MX2015007712A (es) 2012-12-24 2013-12-23 Polipeptidos del factor vii de accion corta.
MX2021002985A MX2021002985A (es) 2012-12-24 2015-06-16 Polipeptidos del factor vii de accion corta.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021002985A MX2021002985A (es) 2012-12-24 2015-06-16 Polipeptidos del factor vii de accion corta.

Country Status (21)

Country Link
US (5) US20150344863A1 (es)
EP (3) EP3572090B1 (es)
JP (3) JP6566869B2 (es)
KR (2) KR102047235B1 (es)
CN (2) CN105025913A (es)
AU (2) AU2013370522B2 (es)
BR (1) BR112015015182B1 (es)
CA (2) CA2896057C (es)
DK (3) DK3572090T3 (es)
ES (3) ES2936485T3 (es)
HK (1) HK1216855A1 (es)
IL (2) IL239345B (es)
MX (2) MX2015007712A (es)
NZ (1) NZ708873A (es)
PE (2) PE20211303A1 (es)
PL (3) PL3165232T3 (es)
SA (1) SA517380867B1 (es)
SG (2) SG10201710593UA (es)
TW (3) TWI681968B (es)
WO (1) WO2014105784A1 (es)
ZA (1) ZA201505315B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211303A1 (es) 2012-12-24 2021-07-20 Coagulant Therapeutics Corp Polipeptidos del factor vii de accion corta
TW201629215A (zh) * 2014-09-30 2016-08-16 拜耳保健有限責任公司 使用凝血酶之組成物及治療方法
KR101755838B1 (ko) 2015-09-09 2017-07-07 현대자동차주식회사 엔진 예열장치 및 그 예열방법
ES2902645T3 (es) * 2016-09-13 2022-03-29 Coagulant Therapeutics Corp Glicoformas del factor VIIA
KR102120921B1 (ko) * 2017-02-10 2020-06-10 주식회사 일리아스바이오로직스 Gba 단백질을 포함하는 엑소솜의 제조 방법 및 상기 제조 방법에 의해 제조된 엑소솜을 유효성분으로 함유하는 고셔병 예방 및 치료용 약학적 조성물
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3008252A (en) 1959-02-02 1961-11-14 Beatrice V Robinson Puffed sleeve ironer
US5180583A (en) 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
FR2632524B1 (fr) * 1988-06-09 1992-03-13 Fondation Nale Transfusion San Procede de preparation d'une fraction concentree en facteur viia et son application a titre de medicament
RU2278123C2 (ru) 2000-02-11 2006-06-20 Максиджен Холдингз Лтд. Молекулы, подобные фактору vii или viia
EP1299126B1 (en) 2000-05-23 2004-10-27 Neurologix, Inc. Glutamic acid decarboxylase (gad) delivery system for treating neurodegenerative diseases
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US20050221335A1 (en) 2001-12-14 2005-10-06 Anthony Kavanagh Reporter gene
PT1499719E (pt) * 2002-04-30 2011-02-09 Bayer Healthcare Llc Variantes polipeptídicas do factor vii ou viia
US7807174B2 (en) 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
US8512710B2 (en) 2002-11-22 2013-08-20 Ansun Biopharma, Inc. Class of therapeutic protein based molecules
ATE431403T1 (de) * 2003-03-20 2009-05-15 Bayer Healthcare Llc Fvii oder fviia varianten
WO2007022512A2 (en) 2005-08-19 2007-02-22 Neose Technologies, Inc. Glycopegylated factor vii and factor viia
RU2373282C2 (ru) * 2003-06-19 2009-11-20 Байер Хелткэр Ллк ВАРИАНТЫ ДОМЕНА GLA ФАКТОРА VII ИЛИ VIIa
US20060198819A1 (en) * 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
ES2381110T3 (es) * 2003-09-09 2012-05-23 Novo Nordisk Health Care Ag Polipéptidos de factor VII de coagulación
US8609370B2 (en) 2004-02-13 2013-12-17 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
CN1981039A (zh) 2004-05-10 2007-06-13 巴斯福植物科学有限公司 组装多表达构建体的方法
EP1761630A2 (en) * 2004-06-21 2007-03-14 Novo Nordisk Health Care AG Glycosylation-disrupted factor vii variants
AU2006222187A1 (en) 2005-03-11 2006-09-14 Fresenius Kabi Deutschland Gmbh Production of bioactive glycoproteins from inactive starting material by conjugation with hydroxyalkylstarch
US20080188400A1 (en) * 2005-04-26 2008-08-07 Maxygen Holdings Ltd. Methods For Treating Bleeding
ES2398574T3 (es) * 2005-07-22 2013-03-20 Bayer Healthcare Llc Activación en solución de factor VII
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
KR20080074166A (ko) * 2005-11-08 2008-08-12 아스테라스 세이야쿠 가부시키가이샤 혈소판감소증을 치료하는 조성물 및 방법
EA015942B1 (ru) * 2006-05-05 2011-12-30 Милленниум Фамэсьютикэлс, Инк. Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
US7532621B2 (en) 2006-08-30 2009-05-12 Cornell Research Foundation, Inc. Lateral error correction for time-critical multicast
TWI519829B (zh) 2006-12-20 2016-02-01 住友化學股份有限公司 偏光板及液晶顯示裝置
CN105056231A (zh) * 2006-12-28 2015-11-18 詹森生物科技公司 用于产生脱唾液酸化免疫球蛋白的方法和载体
BRPI0807768A2 (pt) * 2007-02-20 2014-06-24 Dsm Ip Assests Bv Nova sialidase.
EP2139499A4 (en) 2007-04-26 2010-05-05 Inspiration Biopharmaceuticals RECOMBINANT VITAMIN K-DEPENDENT PROTEINS WITH HIGH SIALIC ACID CONTENT AND METHOD FOR THE PRODUCTION THEREOF
CN101896616B (zh) 2007-10-12 2014-06-04 西格马-奥利奇股份有限公司 提高糖蛋白唾液酸化作用的组合物与方法
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
EP3225252A1 (en) * 2008-05-02 2017-10-04 Laboratoire Français du Fractionnement et des Biotechnologies Treatment of bleeding with low half-life fibrinogen
JP2010022253A (ja) * 2008-07-17 2010-02-04 Kaneka Corp アシアロ糖鎖化合物の作製方法
US9340769B2 (en) 2008-12-05 2016-05-17 The Regents Of The University Of California Methods and compositions for treating P. acnes
US8400974B2 (en) * 2009-07-30 2013-03-19 Apple Inc. Methods and apparatus for providing dynamic information in a wireless information channel
WO2011109600A1 (en) 2010-03-05 2011-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation pattern of a polypeptide
WO2013017555A1 (en) * 2011-08-01 2013-02-07 Lfb-Biotechnologies Factor vii compositions with specific glycosylation for controlled half-life
PE20211303A1 (es) 2012-12-24 2021-07-20 Coagulant Therapeutics Corp Polipeptidos del factor vii de accion corta

Also Published As

Publication number Publication date
TW202026309A (zh) 2020-07-16
NZ749488A (en) 2021-09-24
DK2938351T3 (da) 2019-09-23
US20230295596A1 (en) 2023-09-21
EP2938351B8 (en) 2019-07-31
SG10201710593UA (en) 2018-02-27
BR112015015182A2 (pt) 2019-07-30
KR102047235B1 (ko) 2019-11-22
CA3185756A1 (en) 2014-07-03
ES2746116T3 (es) 2020-03-04
TW201431876A (zh) 2014-08-16
EP2938351A4 (en) 2016-08-24
PE20151206A1 (es) 2015-09-04
ES2936485T3 (es) 2023-03-17
PL3572090T3 (pl) 2023-04-11
JP6363677B2 (ja) 2018-07-25
US20140363419A1 (en) 2014-12-11
BR112015015182B1 (pt) 2023-12-26
US20160376578A1 (en) 2016-12-29
ES2747726T3 (es) 2020-03-11
SA517380867B1 (ar) 2020-06-10
EP2938351B1 (en) 2019-06-26
TWI708783B (zh) 2020-11-01
HK1216855A1 (zh) 2016-12-09
IL273559B (en) 2022-04-01
CA2896057C (en) 2023-03-14
DK3572090T3 (da) 2023-01-09
EP3165232A1 (en) 2017-05-10
ZA201505315B (en) 2022-11-30
US20210002624A1 (en) 2021-01-07
CN107099522A (zh) 2017-08-29
WO2014105784A1 (en) 2014-07-03
SG11201504986QA (en) 2015-07-30
TW201920254A (zh) 2019-06-01
AU2019202663B2 (en) 2020-09-10
EP3572090A1 (en) 2019-11-27
US10273466B2 (en) 2019-04-30
KR20150127573A (ko) 2015-11-17
MX2021002985A (es) 2021-05-14
DK3165232T3 (da) 2019-09-16
TWI743542B (zh) 2021-10-21
NZ708873A (en) 2019-11-29
KR102111934B1 (ko) 2020-05-18
JP2017071608A (ja) 2017-04-13
EP3165232B1 (en) 2019-07-10
AU2019202663A1 (en) 2019-05-09
KR20190072686A (ko) 2019-06-25
PE20211303A1 (es) 2021-07-20
JP2019213540A (ja) 2019-12-19
US10717970B2 (en) 2020-07-21
AU2013370522B2 (en) 2019-01-17
CA2896057A1 (en) 2014-07-03
IL273559A (en) 2020-05-31
EP2938351A1 (en) 2015-11-04
US20150344863A1 (en) 2015-12-03
PL3165232T3 (pl) 2019-12-31
US11530401B2 (en) 2022-12-20
JP6566869B2 (ja) 2019-08-28
AU2013370522A2 (en) 2016-10-06
AU2013370522A1 (en) 2015-07-09
IL239345B (en) 2020-04-30
CN105025913A (zh) 2015-11-04
TWI681968B (zh) 2020-01-11
JP2016507506A (ja) 2016-03-10
EP3572090B1 (en) 2022-12-14
IL239345A0 (en) 2015-07-30
PL2938351T3 (pl) 2020-03-31

Similar Documents

Publication Publication Date Title
MX2021002985A (es) Polipeptidos del factor vii de accion corta.
PH12019500694A1 (en) Factor viii compositions and methods of making and using the same
IL294314A (en) Proteins based on the scaffolding domain of fibronectin that bind to myostatin
MX2016003943A (es) Composiciones y formulaciones para la prevencion y reduccion de tumorigenesis, invasion y proliferacion de celulas de cancer y metodos de produccion y uso en el tratamiento del cancer.
AU2017261625B2 (en) Non-natural consensus albumin binding domains
PH12014501604A1 (en) Polypeptides binding to human complement c5
PH12014502767A1 (en) Interleukin-2 fusion proteins and uses thereof
WO2013151736A3 (en) In vivo production of proteins
MY176820A (en) Egfr and c-met fibronectin type iii domain binding molecules
EA201591367A1 (ru) Соединения резорцина для дерматологического применения
EP4223772A3 (en) Optimized factor viii gene
MX2015015249A (es) Peptidos terapeuticos.
MD4548C1 (ro) Polipeptide care se leagă de CX3CR1
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
EP3747457A3 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
MX2017011794A (es) Composiciones y metodos para diagnosticos y tratamiento del cancer.
WO2014140103A3 (en) Thrombin sensitive coagulation factor x molecules
WO2015081306A3 (en) Peptide tyrosinase activators
WO2010086838A3 (en) Non-ad5 adenoviral vectors and methods and uses related thereto
MX2013001836A (es) Proteina de fusion de fc recombinante del quinto dominio tipo iii de fibronectina de ddc.
WO2013109190A3 (en) Cho-gmt recombinant protein expression
WO2015054439A3 (en) Hybrid factor viii polypeptides for use to treat hemophilia a
PH12016501132A1 (en) A process for preparing a composition of pegylated proteins
WO2014115087A3 (en) A method for the preparation of recombinant human prothrombin and fibrinogen
AR118705A2 (es) Polipéptido del factor vii para tratar enfermedades, método para prepararlo y composición que lo contiene